MIRA CEO 出售 1.29 亿美元的股票，获得较大的选项奖项在晚期 5 式披露

summarizeSummary

This Form 5 filing discloses several significant insider transactions by MIRA Pharmaceuticals' CEO and Chairman, Erez Aminov, that occurred in 2025 but were reported late. The most impactful event is the sale of 613,595 shares of common stock for approximately $1.29 million in October 2025. This substantial disposition by a key executive, following the exercise of options, signals a reduction in direct ownership and could be interpreted as a move to realize gains or for liquidity. Concurrently, the CEO received a very large grant of 3,155,170 stock options/RSUs in December 2025, which vested immediately. While this constitutes significant compensation, the potential dilution from such a large grant (representing over 7% of the company's current market capitalization in potential shares) could be a concern for investors. The combination of a material insider sale and a substantial dilutive compensation package suggests a negative market impact.

check_boxKey Events

• 重要的股票期权/RSU授予

  阿明诺夫于2025年12月17日获得3,155,170股权期权/RSU的奖励，立即到期。

• 可行权选项

  阿明诺夫于2025年10月16日行使了613,595张股票期权，紧随股权出售而来。

• 延迟披露

  这些交易于2025年3月、10月和12月的交易已在2026年2月17日提交的表格5中报告。

auto_awesomeAnalysis

This Form 5 filing discloses several significant insider transactions by MIRA Pharmaceuticals' CEO and Chairman, Erez Aminov, that occurred in 2025 but were reported late. The most impactful event is the sale of 613,595 shares of common stock for approximately $1.29 million in October 2025. This substantial disposition by a key executive, following the exercise of options, signals a reduction in direct ownership and could be interpreted as a move to realize gains or for liquidity. Concurrently, the CEO received a very large grant of 3,155,170 stock options/RSUs in December 2025, which vested immediately. While this constitutes significant compensation, the potential dilution from such a large grant (representing over 7% of the company's current market capitalization in potential shares) could be a concern for investors. The combination of a material insider sale and a substantial dilutive compensation package suggests a negative market impact.